Skip to main content
BIOXYNE LIMITED logo

BIOXYNE LIMITED — Investor Relations & Filings

Ticker · BXN ISIN · AU000000BXN6 LEI · 984500F02D2B1B94E956 ASX Manufacturing
Open in API
Filings indexed 843 across all filing types
Latest filing 2019-09-29 Annual Report
Country AU Australia
Listing ASX BXN

About BIOXYNE LIMITED

https://bioxyne.com

Bioxyne Limited is a life sciences company focused on the development, manufacture, and commercialization of health and wellness products. The company specializes in proprietary probiotic strains, notably the Lactobacillus fermentum VRI-003 (PCC), which is utilized in supplements targeting immune health and gut function. Following the acquisition of Breathe Life Sciences, Bioxyne has expanded its portfolio into the medicinal cannabis sector, novel foods, and consumer health products. Its operations encompass the production and distribution of pharmaceutical-grade cannabis products, CBD-based wellness items, and functional supplements. The company serves international markets through a vertically integrated model, focusing on research-driven formulations and high-quality manufacturing standards to address growing consumer demand for therapeutic and preventative health solutions.

Recent filings

Filing Released Lang Actions
Annual Report to shareholders 57 pages 1.0MB
Annual Report Classification · 100% confidence The document is titled 'Annual Report for the Year Ended 30 June 2019' and contains detailed sections typical of an annual report, including Chairman's Letter, Corporate Governance Statement, Directors' Report, Auditor's Independence Declaration, Consolidated Financial Statements, Notes to the Financial Statements, Directors' Declaration, and Independent Auditor's Report. The content includes comprehensive financial data, operational review, governance information, and detailed disclosures consistent with a full annual report. The document length is 15,000 characters, indicating it is a full report rather than a brief announcement or summary. Therefore, this document fits the definition of an Annual Report (10-K). FY 2019
2019-09-29 English
Preliminary Final Report 36 pages 535.9KB
Annual Report Classification · 95% confidence The document is titled 'APPENDIX 4E' and contains detailed financial statements including consolidated statements of profit or loss, financial position, changes in equity, and cash flows for the year ended 30 June 2019. It includes comprehensive financial data, notes on accounting policies, and commentary on results. The reporting period is a full fiscal year (twelve months to 30 June 2019). The document is about 15,000 characters long, indicating it is a full report rather than a brief announcement. The presence of full financial statements and detailed notes aligns with an Annual Report filing. The document is not a brief announcement, certification, or a regulatory filing of miscellaneous nature. Therefore, the document is best classified as an Annual Report (10-K equivalent) for the fiscal year ending 30 June 2019. FY 2019
2019-08-27 English
Appendix 4C - quarterly 8 pages 526.0KB
Interim / Quarterly Report Classification · 100% confidence The document is titled 'QUARTERLY REPORT FOR THE QUARTER ENDED 30 JUNE 2019' and contains detailed financial data including sales revenues, cash flow statements, and operational updates for the quarter. It includes a consolidated statement of cash flows, reconciliation of cash and cash equivalents, and a compliance statement prepared in accordance with accounting standards. The document is over 13,000 characters long, indicating it is a substantive report rather than a brief announcement. The presence of detailed financial statements and analysis for a period shorter than a full fiscal year aligns with the definition of an Interim / Quarterly Report (IR). There is no indication that this is merely an announcement or certification, nor does it fit other categories such as Annual Report or Earnings Release. Therefore, the correct classification is IR (Interim / Quarterly Report). Q4 2019
2019-07-30 English
Change of Director's Interest Notice 3 pages 198.6KB
Director's Dealing Classification · 100% confidence The document is titled 'Appendix 3Y Change of Director’s Interest Notice' and references ASX listing rule 3.19A.2 and section 205G of the Corporations Act. It details the change in securities holdings of a company director, including number of shares held before and after the change, nature of the interest, and transaction details. The document is a formal notification of a director's personal share transactions. It does not contain financial statements, management discussion, or other report content. This matches the definition of 'Director's Dealing' filings, which report personal share transactions by company directors and executives (insider trades). The document length is 3631 characters, consistent with a short notice rather than a full report. Therefore, the correct classification is DIRS.
2019-06-03 English
Appendix 4C - quarterly 7 pages 363.2KB
Interim / Quarterly Report Classification · 100% confidence The document is titled 'QUARTERLY REPORT FOR THE QUARTER ENDED 31 MARCH 2019' and contains detailed financial data including sales revenues, cash flow statements, cash equivalents, payments to directors, and compliance statements. It references the Australian Stock Exchange Listing Rule 4.7B, which mandates quarterly reporting. The document includes actual financial statements and substantive financial data for a quarter, not just an announcement or summary. The length of the document (over 11,000 characters) and the detailed financial tables confirm it is a full quarterly report rather than a brief announcement or certification. Therefore, the document fits the definition of an Interim / Quarterly Report (IR). Q3 2019
2019-04-28 English
Market Update 3 pages 260.7KB
Regulatory Filings Classification · 90% confidence The document is an ASX announcement dated 1 April 2019 titled 'Bioxyne – Market Update'. It provides updates on the company's operations in Indonesia, Malaysia, China, and other parts of Asia, including sales progress, regulatory constraints, and a settlement of litigation. The content focuses on operational and market developments rather than financial results or detailed financial statements. The document length is 4598 characters, which is relatively short and reads like a market update or operational progress report rather than a full financial report or earnings release. There is no indication of quarterly or annual financial results, no detailed financial data, and no mention of earnings or management discussion of financial performance. It is not a report publication announcement since it contains substantive operational updates. The document fits best into the category of a Capital/Financing Update (CAP) or Regulatory Filings (RNS). However, since it is an ASX announcement providing a market update on operations and litigation settlement, it aligns more closely with Regulatory Filings (RNS), which is the fallback for miscellaneous regulatory announcements that do not fit other categories. Therefore, the classification is Regulatory Filings (RNS) with high confidence.
2019-03-31 English

Browse filings by year

25 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.